Business
3SBio Unveils 2024 Annual Results: Profit Surges 34.9% YoY, Innovation Pipeline Delivers Strong Value
3SBio Unveils 2024 Annual Results: Profit Surges 34.9% YoY, Innovation Pipeline Delivers Strong
About this update from 3sbio, Inc.
[{"type":"text","content":"Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2024 annual results. According to its results announcement, revenue in 2024 grew by 16.5% year on year to approximately RMB 9.108billion. Gross profit added 17.9% year on year to approximately RMB 7.828billion. Net profit attributable to owners of the parent rose 34.9% year on year to approximately RMB 2.09 billion. Net profit attributable to owners of the parent adjusted for non-operating items was approximately RMB 2.318billion, up 18.8% over the same period last year. The board of directors of 3SBio proposed to declare a final dividend of HKD 0.25 per share for the year ended 31 December 2024.\n \n Revenue approaching RMB 10 billion milestone\n \n In 2024, 3SBio achieved strong revenue growth, with total revenue approaching the RMB 10 billion mark. Sales of TPIAO, the Company's flagship product and the world's only commercial recombinant human thrombopoietin (rhTPO), totaled RMB 5.062 billion in 2024, reflecting a year-on-year increase of 20.4%. TPIAO has been listed with the highest-level recommendation in several clinical guidelines, including the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the Diagnosis and Treatment of Cancer Therapy Induced Thrombocytopenia (CTIT) (2024 Edition). In 2024, the product received approval for the treatment of primary immune thrombocytopenia in children and adolescents and achieved a renewal in the 2024 National Reimbursement Drug List (NRDL).\n \n EPIAO and SEPO, the recombinant human erythropoietins (rhEPO), maintained their dominant market positions. Yisaipu continued to strengthen its leadership in the domestic market, achieving steady sales growth through proactive market expansion. Cipterbin delivered strong performance, with increasing recognition in clinical applications and longer patient treatment cycles, all of which contributed to rapid sales growth.\n \n In 2024, Mandi, a leading hair loss treatment, achieved sales of RMB 1.337 billion, marking a 18.9% year-on-year increase. The product continued to strengthen its reputation as a science-backed hair growth brand, with its digital marketing system expanding and e-commerce sales rising. Additionally, the approval of Mandi's foam formulation provided patients with a new treatment option, further solidifying Mandi's dominant positio...